Acetylcholine Receptor Blocking Antibody

ACEBLK

34459

1 mL serum

0.5 mL

Room temperature

Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days

Gross hemolysis • Grossly lipemic • Microbially contaminated

Set up: Sun, Tues, Thurs; Report available: 3-6 days

Antibodies may not be found in congenital myasthenia.

<15 % Inhibition

Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR blocking autoantibodies prevent inter-action of binding antibodies with the AChR. Fewer than 1% of patients have blocking antibodies without binding antibodies. Blocking antibodies are present in about 50% of patients with MG, but rare in other conditions. Therefore, blocking antibodies have utility in ruling out a possible false positive binding assay and detecting the rare patient without AChR binding antibodies.